Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P51843
UPID:
NR0B1_HUMAN
Alternative names:
DSS-AHC critical region on the X chromosome protein 1; Nuclear receptor DAX-1
Alternative UPACC:
P51843; Q96F69
Background:
Nuclear receptor subfamily 0 group B member 1 (NR0B1), also known as DAX-1, plays a pivotal role in the development of the hypothalamic-pituitary-adrenal-gonadal axis. It functions as an orphan nuclear receptor and a coregulatory protein that inhibits the transcriptional activity of other nuclear receptors. NR0B1 is also implicated in embryo development and the maintenance of embryonic stem cell pluripotency.
Therapeutic significance:
NR0B1 is linked to congenital adrenal hypoplasia and 46,XY sex reversal 2, diseases characterized by adrenal insufficiency and sex reversal, respectively. Understanding the role of NR0B1 could lead to novel therapeutic strategies for these conditions.